GiiConference.com: Drug Discovery Chemistry 2012 in San Diego
Register for the Drug Discovery Chemistry 2012 conferences taking place April 17-19, 2012.
Farmington, CT, February 23, 2012 --(PR.com)-- Global Information Inc. (GII) is pleased to announce Drug Discovery Chemistry 2012. The six conferences takes place from April 17-19, 2012 in San Diego, California, USA.
For more information about the conference, visit: http://www.giiconference.com/chi214649-2012/
1. The Challenge of Antibacterial Drug Development
For quite some time now, the lack of new antibacterials has been broadly recognized as a major unmet medical need. To successfully tackle antibacterial resistance, screening for novel targets and developing new strategies to interfere with bacteria are just as important as other challenges, including predicting toxicology, selectivity, resistance, permeability and pk of a new lead, and creating new models for optimization of leads and compounds. This conference is designed to bring together executive level scientists from the academic, pharmaceutical and biotech areas to discuss progress, novel insight, lessons learned and current bottlenecks.
2. Fragment-Based Drug Discovery
Finding fragments by various screening methods has become an established practice. Each of the technologies used have a different set of advantages and disadvantages. Questions such as how to select the most suitable projects, how and when to use screening methods such as crystallography, NMR, SPR or mass spec either as a standalone technique or in combination and how to correctly predict binding at active sites will be addressed in this meeting. In addition, new challenges are arising and will be discussed, such as fragment docking, fragment library design, ligand efficiency, fragment selectivity and specificity.
3. Anti-Inflammatories: Small Molecule Approaches
JAK kinase inhibitors will probably be the first new class of oral anti-inflammatories on the market, with the first one likely to receive approval end of 2012. But which JAK or combinations of JAK enzymes is going to prove the best to inhibit in terms of side effects and overall risk benefit profile to patients? How are the other kinase inhibitors aimed at targeting SYK and BTK, targeted for autoimmune disease but with broader potential in diseases such as cancer, progressing?
4. Physicochemical Drug Properties
The optimization of physical properties of a compound is fundamental to the drug discovery process, mainly due to their influence on absorption and distribution in vivo. This provides insight into the in vivo transport processes and knowing the properties will help with choosing the optimal compounds for the task. It saves costs and time when compounds are being properly analyzed in the design stage before they are moving into development, as it is important to consider questions such as how hydrophobicity will affect the solubility of a drug down the line or how the charge of the compound interacts with the absorption by a transport mechanism. Also, the use of predictive models is important, but again, without consideration of the actual physical chemical property of the new compound, the analyses will be based on a different set of data. This meeting will discuss what it takes to create selective and efficacious compounds and to understand the biological data by analyzing the physicochemical properties early on.
5. Protein-Protein Interactions as Drug Targets
6. HCV Drug Discovery: Targeting Viral and Host Proteins
About Global Information Inc. (GII)
GII Global Conferences and Events (http://www.giiconference.com/) is the conference and exhibitions arm of leading market research provider, Global Information Inc. GII partners with leading international event organizers to provide over 2,400 world class industry conferences, exhibitions, and networking events on a wide range of focus areas including Life Sciences; Biotechnology and Pharmaceuticals; Telecoms and Information Technology; Building and Construction; Manufacturing and Materials; Banking; Energy and Sustainability.
###
For more information about the conference, visit: http://www.giiconference.com/chi214649-2012/
1. The Challenge of Antibacterial Drug Development
For quite some time now, the lack of new antibacterials has been broadly recognized as a major unmet medical need. To successfully tackle antibacterial resistance, screening for novel targets and developing new strategies to interfere with bacteria are just as important as other challenges, including predicting toxicology, selectivity, resistance, permeability and pk of a new lead, and creating new models for optimization of leads and compounds. This conference is designed to bring together executive level scientists from the academic, pharmaceutical and biotech areas to discuss progress, novel insight, lessons learned and current bottlenecks.
2. Fragment-Based Drug Discovery
Finding fragments by various screening methods has become an established practice. Each of the technologies used have a different set of advantages and disadvantages. Questions such as how to select the most suitable projects, how and when to use screening methods such as crystallography, NMR, SPR or mass spec either as a standalone technique or in combination and how to correctly predict binding at active sites will be addressed in this meeting. In addition, new challenges are arising and will be discussed, such as fragment docking, fragment library design, ligand efficiency, fragment selectivity and specificity.
3. Anti-Inflammatories: Small Molecule Approaches
JAK kinase inhibitors will probably be the first new class of oral anti-inflammatories on the market, with the first one likely to receive approval end of 2012. But which JAK or combinations of JAK enzymes is going to prove the best to inhibit in terms of side effects and overall risk benefit profile to patients? How are the other kinase inhibitors aimed at targeting SYK and BTK, targeted for autoimmune disease but with broader potential in diseases such as cancer, progressing?
4. Physicochemical Drug Properties
The optimization of physical properties of a compound is fundamental to the drug discovery process, mainly due to their influence on absorption and distribution in vivo. This provides insight into the in vivo transport processes and knowing the properties will help with choosing the optimal compounds for the task. It saves costs and time when compounds are being properly analyzed in the design stage before they are moving into development, as it is important to consider questions such as how hydrophobicity will affect the solubility of a drug down the line or how the charge of the compound interacts with the absorption by a transport mechanism. Also, the use of predictive models is important, but again, without consideration of the actual physical chemical property of the new compound, the analyses will be based on a different set of data. This meeting will discuss what it takes to create selective and efficacious compounds and to understand the biological data by analyzing the physicochemical properties early on.
5. Protein-Protein Interactions as Drug Targets
6. HCV Drug Discovery: Targeting Viral and Host Proteins
About Global Information Inc. (GII)
GII Global Conferences and Events (http://www.giiconference.com/) is the conference and exhibitions arm of leading market research provider, Global Information Inc. GII partners with leading international event organizers to provide over 2,400 world class industry conferences, exhibitions, and networking events on a wide range of focus areas including Life Sciences; Biotechnology and Pharmaceuticals; Telecoms and Information Technology; Building and Construction; Manufacturing and Materials; Banking; Energy and Sustainability.
###
Contact
Global Information Inc.
Yuko Ueki
860-674-8796
http://www.giiconference.com/
Yuko Ueki
860-674-8796
http://www.giiconference.com/
Contact
Categories